- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00108706
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lowering blood pressure reduces the risk of first ever and recurrent stroke. There is extensive evidence that blood pressure should be lowered following acute stroke, even from so called normal levels. However, it is not clear how soon after acute stroke that blood pressure should be lowered. Observational studies have demonstrated increased mortality with both high and low blood pressure. The optimal management of blood pressure in the immediate post-stroke period remains controversial.
Although uncertainty exists with regard to lowering blood pressure in the acute stages of stroke, two large randomised controlled trials have demonstrated unequivocally that intense management of blood pressure started >4 weeks from the onset of stroke significantly reduces the risk of recurrent stroke. Both of these trials have used an Angiotensin Converting Enzyme Inhibitor (ACE-I) based regime. It has been proposed that these benefits may be due to a direct result of the ACE-I rather than blood pressure lowering per se. Similar vasculoprotective effects have been seen in ARBs, but evidence of their safety and efficacy in acute stroke is limited to those patients with the highest blood pressures (>200/110). The trial (ACCESS) was terminated prematurely due to a positive imbalance in favour of intervention with the ARB Candesartan. If such interventions are to convey potential benefit they need to be started as soon as possible following the acute event in order that the ischaemic cascade which leads to neuronal death may be modified. Further research is first required in order to demonstrate their safety and efficacy when used in this way.
ACCOST is a two phase randomised controlled trial designed to address this important research question. Phase I is a four week double blind placebo controlled phase where patients receive either Candesartan 4 mg daily or matched placebo, with no blood pressure treatment target. A treatment titration step occurs after two weeks where, subject to titration criteria, subjects will receive either Candesartan 8 mg daily or matched placebo. After the first four weeks, the subjects are unblinded and enter Phase II of the trial. Phase II is an eight week open label comparison of Candesartan and 'usual care' with an ACE-I based treatment regime. Blood pressure is now treated to reach the British Hypertension Society target blood pressure of <140/85, with or without additional therapy.
Blinded outcome measures will include neurological recovery based on the National Institutes of Health Stroke Scale, as well as functional recovery. Incidence of first dose hypotension and changes in renal function will also be collected.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tyne and Wear
-
Sunderland, Tyne and Wear, United Kingdom, SR4 7TP
- Sunderland Royal Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute ischaemic stroke <72 hours from symptom onset (CT proven)
- Medically stable with no evidence of acute infection and not receiving antibiotic therapy
- Neurologically stable (no progression on NIHSS)
- Able to swallow unthickened fluids safely
- Mean BP (blood pressure) >120/70 in unaffected arm
Exclusion Criteria:
- Previous severe disability (Modified Rankin Score >2)
- Nursing home residents
- Previous history of congestive heart failure requiring treatment with ACE-Inhibitors or angiotensin receptor blockers
- Renal impairment (creatinine >200 mcgmol/L)
- Women of child bearing potential
- Minors <18 years of age
- History of dementia without ability to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Mortality (all causes)
|
Mortality (vascular causes)
|
Secondary Outcome Measures
Outcome Measure |
---|
Neurological Recovery (NIHSS [National Institutes of Health Stroke Scale])
|
Functional Recovery (Modified Rankin/Barthel)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christopher S Gray, MD, University of Newcastle Upon-Tyne
Publications and helpful links
General Publications
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41. doi: 10.1016/S0140-6736(01)06178-5. Erratum In: Lancet 2001 Nov 3;358(9292):1556. Lancet 2002 Jun 15;359(9323):2120.
- Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301. Erratum In: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748.
- Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003 Jul;34(7):1699-703. doi: 10.1161/01.STR.0000075777.18006.89. Epub 2003 Jun 19.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Candesartan
Other Study ID Numbers
- Accost
- CTA Number:21763/0001/001
- EudraCT Number:2004-001847-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrovascular Accident
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation...CompletedStroke | Vascular Accident, Brain | Stroke, Acute | Cerebrovascular Accident | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, Acute | Apoplexy | CVA | Cerebrovascular ApoplexyCanada
-
Sheba Medical CenterCompletedLate Effects of Cerebrovascular Accident
-
Universitaire Ziekenhuizen KU LeuvenCompletedTranscranial Direct Current Stimulation | Cerebrovascular Accident (CVA)Belgium
-
Sunnyview Rehabilitation HospitalRecruitingStroke | Stroke, Acute | Cerebrovascular Accident | Cerebrovascular Accident, AcuteUnited States
-
Peking University Third HospitalAstraZeneca Investment (China) Co., LtdCompletedCerebrovascular Accident | Cerebrovascular Accident, AcuteChina
-
Medical University of South CarolinaIcahn School of Medicine at Mount SinaiCompletedIschemic Cerebrovascular AccidentUnited States
-
John DavidsonWashington University School of MedicineWithdrawnIschemic Cerebrovascular AccidentUnited States
-
University of California, IrvineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingStroke, Ischemic | Cerebrovascular Accident (CVA)United States
-
Parker Hannifin CorporationCedars-Sinai Medical Center; Kessler Foundation; TIRR Memorial Hermann; Shirley... and other collaboratorsCompletedStroke | Hemiplegia | Cerebrovascular Accident (CVA)United States
-
University Hospital, Strasbourg, FranceRecruitingCerebrovascular Accident (CVA)France
Clinical Trials on Candesartan
-
GlaxoSmithKlineCompleted
-
AstraZenecaCompletedNon-diabetic Nephropathy With HypertensionKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedCardiovascular DiseaseIndia
-
TakedaCompleted
-
St. Olavs HospitalUllevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaboratorsActive, not recruiting
-
AstraZenecaTakedaCompleted
-
Huazhong University of Science and TechnologyUnknown
-
AstraZenecaCompleted
-
Herlev HospitalUnknownCardiovascular Diseases | Kidney Failure, ChronicDenmark